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The naturally occurring clonal diversity among field isolates of the major human malaria parasite Plasmodium 
vivax remained unexplored until the early 1990s, when improved molecular methods allowed the use of blood sam-
ples obtained directly from patients, without prior in vitro culture, for genotyping purposes. Here we briefly review 
the molecular strategies currently used to detect genetically distinct clones in patient-derived P. vivax samples, 
present evidence that multiple-clone P. vivax infections are commonly detected in areas with different levels of 
malaria transmission and discuss possible evolutionary and epidemiological consequences of the competition be-
tween genetically distinct clones in natural human infections. We suggest that, when two or more genetically distinct 
clones are present in the same host, intra-host competition for limited resources may select for P. vivax traits that 
represent major public health challenges, such as increased virulence, increased transmissibility and antimalarial 
drug resistance. 
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Plasmodium vivax is the most widespread human 
malaria parasite, causing an estimated 132-391 million 
episodes of disease each year (Hay et al. 2004), with 2.6 
billion people at risk of infection worldwide (Guerra et 
al. 2006). Outside of Africa, P. vivax is the main cause 
of malaria morbidity, with an enormous, but largely 
overlooked, public health burden. Historically, P. vivax 
malaria has received little attention and limited funds 
for research and control, since it usually produces less 
severe symptoms than Plasmodium falciparum (Price 
et al. 2007). With the recent emergence of drug resis-
tance (Baird 2004) and increased virulence (Rogerson 
& Carter 2008) among P. vivax strains, considerable re-
search efforts devoted to the study of this parasite are 
now underway. 
 In vitro cloning protocols developed in the early 
1980s allowed for the phenotypic characterization of ge-
netically diverse lineages of P. falciparum co-infecting 
the same host (Rosario 1981). The same strategy could 
not, however, be immediately applied to other human 
malaria parasites due to the lack of practical methods for 
their long-term propagation and cloning in vitro (Udom-
sangpetch et al. 2008). The clonal diversity of natural 
P. vivax infections in humans remained unexplored un-
til the early 1990s. At that time, advances in molecular 
methods - particularly with the implementation of poly-
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merase chain reaction (PCR)-based protocols to amplify 
parasite DNA - allowed for the genotyping of malaria 
parasite samples obtained directly from patient blood 
without a preceding in vitro culture step (Kimura et al. 
1990). Over the following years, these techniques re-
vealed that multiple-clone (also known as mixed-strain) 
P. vivax infections are very common in areas with quite 
variable levels of malaria transmission. 
Here, we briefly review the methods currently used to 
investigate the clonal diversity of patient-derived P. vivax 
samples, present available estimates for the prevalence of 
multiple-clone P. vivax infections worldwide and discuss 
possible evolutionary and epidemiological consequences 
of the co-occurrence of genetically distinct clones of this 
major parasite in natural human infections.
 
Varying detection methods 
 
The earliest attempts to investigate the genetic diver-
sity of P. vivax isolates relied on the use of monoclonal 
antibodies or isoenzymes to characterize phenotypes 
(Udagama et al. 1987, 1990, Joshi et al. 1989). This ap-
proach could only be applied to blood samples with rel-
atively high parasitaemias. Over the last two decades, 
the detection of multiple-clone infections has improved 
substantially with the use of a greater number of poly-
morphic molecular markers. The specific PCR-based 
amplification of parasite DNA, alone or accompanied by 
DNA sequencing or restriction analysis, made possible 
the sensitive detection of diversity at the genome level 
while bypassing the requirement for in vitro propagation 
of parasites (Cui et al. 2003a). More recently, the use of 
high-fidelity multiple displacement amplification tech-
nology (Dean et al. 2002) for whole-genome amplifica-
tion of malaria parasite DNA prior to PCR (Karunaweera 
et al. 2007, 2008, Wang et al. unpublished observations) 
has further extended the applicability of molecular 
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methods to samples containing limited amounts of DNA 
template, thus allowing for more comprehensive large-
scale genotyping studies of P. vivax.
The first molecular markers used for P. vivax studies 
were orthologues of the ones already described in P. fal-
ciparum. The recent completion of the sequence of the P. 
vivax genome (Carlton et al. 2008) has, however, opened 
the doors for discovery of novel single-nucleotide poly-
morphisms (Feng et al. 2003) and highly polymorphic 
microsatellite markers (Inwong et al. 2006, Karunaweera 
et al. 2007). Earlier molecular studies of P. vivax diver-
sity focused on antigen-coding single-copy genes, such 
as merozoite surface protein-1 (MSP-1), merozoite sur-
face protein-3α (MSP-3α), circumsporozoite protein 
(CSP) and apical membrane antigen-1. Additional focus 
was placed on markers of antimalarial drug resistance, 
such as mutations in the gene coding for dihydrofolate 
reductase, due to their importance for vaccine develop-
ment and drug resistance surveillance. The patterns of 
diversity revealed by these markers reflect the combined 
effects of the parasite′s population history and selective 
constraints imposed by the host′s immunity or antima-
larial drug use (Escalante et al. 2004). Thus, these mark-
er types are not very informative about the population 
structure of this species as a whole. 
The current markers of choice for large-scale popu-
lation genetic studies of eukaryotes are the highly poly-
morphic short (1-6 bp long) tandem repeats known as 
microsatellites (Schlotterer 1998). Microsatellite mark-
ers are not as abundant across the genome of P. vivax 
(Feng et al. 2003, Carlton et al. 2008) as they are in that 
of P. falciparum (Joy et al. 2004). In addition, it was ini-
tially suggested that there was little polymorphic varia-
tion at these microsatellites among worldwide isolates 
(Leclerc et al. 2004). However, highly variable micro-
satellite markers have been more recently described and 
used in population-level studies of genetic variation in 
this species (Gomez et al. 2003, Imwong et al. 2006, 
2007a, b, Ferreira et al. 2007, Karunaweera et al. 2007, 
2008, Carlton et al. 2008). 
Microsatellite repeat variation is usually free of 
strong selective constraints (Joy et al. 2004). Microsat-
ellites can also be effectively used to detect genetically 
distinct clones in patients, although some challenges re-
main in the interpretation of the genotyping results. For 
example, minor alleles (those corresponding to less abun-
dant clones) can theoretically be differentiated from the 
predominant allele by measuring the relative abundance 
of the respective PCR amplicons, which are labelled 
with fluorescent dyes, following electrophoretic sepa-
ration with automated DNA sequencers. This strategy 
permits classification of the predominant multilocus 
haplotype in clone mixtures, based on the unique com-
bination of the most abundant alleles at each locus ana-
lyzed (Anderson et al. 1999). We recently used mixtures 
of genomic DNA from two genetically distinct P. vivax 
isolates from Brazil to investigate how accurately micro-
satellite genotyping describes the overall genetic diver-
sity and characterizes multilocus haplotypes in multiple-
clone infections. We found varying PCR amplification 
efficiencies of microsatellite alleles (Fig. 1), suggesting 
that amplification biases may lead to the inaccurate as-
signment of predominant haplotypes in multiple-clone 
P. vivax infections (Havryliuk et al. 2008). 
In addition, minor alleles may be confused with ar-
tefacts such as stutter peaks or unspecific PCR amplifi-
cation products (Fig. 2). Stutter peaks result from DNA 
strand slippage during PCR at intervals corresponding to 
nucleotide repeat sizes (de Valk et al. 2007). A minimum 
value of either one-third (Anderson et al. 2000, Imwong 
et al. 2007a, Karunaweera et al. 2008) or one-fourth 
(Anderson et al. 1999) of the predominant allele peak 
height has been used as a cut-off to differentiate minor 
alleles from stutter or unspecific peaks, but the sensitiv-
ity and specificity of these criteria remain undetermined 
(Greenhouse et al. 2006, Havryliuk et al. 2008).  
Although most studies consider an infection to con-
tain multiple clones if more than one allele is found for 
at least one microsatellite locus, others follow more 
stringent requirements. These strict criteria have been 
suggested because the detection of two or more alleles 
at some microsatellite loci may be a result of any of the 
artefacts mentioned above, which could potentially lead 
to an overestimation of the proportion of multiple-clone 
infections. Imwong et al. (2007a) observed great drops in 
multiple-clone infection detection rates in P. vivax iso-
lates from South America and Asia as the requirement 
for the number of microsatellite loci with multiple alleles 
Fig. 1: electropherograms for two microsatellite markers, amplified 
from the same mixture of genomic DNA from two Plasmodium vivax 
clones (here identified as clone 1 and clone 2). Y-axis shows arbi-
trary fluorescence units; notice varying fluorescence scales for each 
microsatellite. X-axis represents DNA fragment size in bp and filled 
peaks correspond to the Genescan 500HD Rox size standard used. 
For microsatellite MS5 (A), the peak corresponding to the allele found 
in clone 1 is higher than that of clone 2 (peak height ratio, 2.4:1). An 
opposite pattern is found for microsatellite MS9 (B), for which the al-
lele corresponding to clone 2 has been preferentially amplified (peak 
height ratio, 2.9:1). However, these markers were amplified from the 
same mixture of clones, with a constant proportion of genomic DNA 
from clones 1 and 2.
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grew. Similar results were recently found in an exten-
sive study of microsatellite variation of P. vivax isolates 
from Mexico (Joy et al. 2008). Nevertheless, detection of 
parasite clones co-infecting the same host that differ at 
only one of the 10 or even 20 microsatellite loci analyzed 
is not necessarily artificial. A careful analysis of P. falci-
parum clones obtained from patients naturally infected 
in areas of very low transmission revealed that clone 
mixtures usually comprise genetically related parasites. 
A possible explanation for this is that they descended 
from the same parental clones, which had recombined 
during the sexual phase of the parasite’s life cycle in the 
mosquito vector (Druilhe et al. 1998). If this is also the 
case for P. vivax malaria, the use of more stringent cri-
teria might grossly underestimate the clonal diversity of 
natural infections.
 Augmenting the number of markers increases the 
possibility of detecting multiple clones. For example, in 
90 P. vivax isolates from Thailand, Cui et al. (2003b) 
found a multiple-clone infection rate of 25.6% using the 
CSP gene alone, 19.3% using MSP-3α alone and 35.6% 
when the two markers were combined. A similar trend 
was observed in the analysis of 141 isolates from India 
described by Kim et al. (2006). 
With the growing use of microsatellite genotyping, it 
becomes more important to define an optimal range for 
the number of markers that would accurately estimate 
multiple-clone infection rates without incurring unnec-
essary cost. As a first attempt to determine the mini-
mum number of microsatellite markers required to score 
all multiple-clone infections in a population, we used a 
dataset comprising 39 multiple-clone infections found in 
77 P. vivax isolates from Brazil (Ferreira et al. 2007). 
We first ranked the 14 microsatellite markers analyzed 
according to their discriminatory ability, which was es-
timated by calculating their virtual heterozygosity (HE) 
values. Virtual heterozygosity is defined as HE = [n/(n 
– 1)][1- ∑pi
2], where n is the number of isolates analyzed 
and pi is the frequency of the i-th allele in the population. 
Values range between 0-1. Virtual heterozygosity, in this 
context, gives the average probability that a pair of al-
leles randomly obtained from the population is different. 
It is synonymous with the Simpson′s index of diversity, 
which has previously been suggested by Hunter and 
Gaston (1988) as a means to evaluate the discriminatory 
ability of genotyping systems for bacterial strains. We 
then used the marker with the highest HE to estimate the 
percent of multiple-clone infections detected (28% of the 
total multiple-clone infections). The rest of the markers, 
in order of decreasing HE values, were added one at time 
to our analysis. As shown in Fig. 3, we found that all of 
the multiple-clone infections could be detected with the 
use of only 11 markers and that 90% could be detected 
with nine markers. This suggested that an even smaller 
number of markers could probably be used in the future 
genotyping studies of multiple-clone infections. Further 
Fig. 2: electropherogram for microsatellite MS4 amplified from a 
mixture of genomic DNA from two Plasmocium vivax clones. Y-axis 
shows arbitrary fluorescence units and x-axis represents DNA frag-
ment size in bp. Filled peaks correspond to the Genescan 500HD Rox 
size standard used. Note that stutter peaks (arrows) are found for both 
the major allele (clone 1) and the minor allele (clone 2). 
Fig. 3: relationship between the number of microsatellite markers 
typed and percent of multiple-clone infections detected. The sample 
set comprised 39 multiple-clone infections detected in 77 Plasmo-
dium vivax isolates from state of Acre, Brazil (Ferreira et al. 2007). 
The markers were added one by one in decreasing order of virtual 
heterozygosity (HE) values. By combining 11 markers (MS16, MS8, 
MS20, MS9, MS4, MS5, MS10, MS1, MS6, MS15, and MS7) all multi-
ple-clone infections were detected.
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estimates for the optimal number of microsatellite mark-
ers are required for populations in other geographic ar-
eas, given that the HE values of markers might vary. 
Numerous molecular markers are finally becoming 
available for the comprehensive description of P. vivax 
diversity. However, this multitude of methods also com-
promises the ability to compare multiple-clone infection 
rates across different studies. The application of stan-
dardized genotyping protocols in the future promises to 
overcome this setback.
Prevalence and consequences of multiple-clone 
P. vivax infections
The use of different molecular markers led to the de-
tection of widely variable proportions of multiple-clone 
P. vivax infections worldwide (Table) (Joshi et al. 2008). 
In general, multilocus analysis, such as microsatellite 
genotyping, detected greater numbers of multiple-clone 
infections when compared to single-locus analysis. The 
extensive clonal diversity of P. vivax infections in areas 
with relatively low malaria transmission, such as in Bra-
zil and Colombia, is particularly surprising (Ferreira et 
al. 2007, Imwong et al. 2007b). The only published com-
parison of microsatellite diversity in two human malaria 
parasite species co-circulating in the same area suggests 
that P. vivax infections comprise multiple clones (12 
multiple-clone infections among 25 isolates typed) more 
often than P. falciparum infections (6 multiple-clone 
infections among 34 isolates typed) in rural Amazonia 
(Ferreira et al. 2007). Parasite relapses provide a biologic 
basis for increased clonal diversity in P. vivax isolates, 
especially when compared to non-relapsing species such 
as P. falciparum. The dormant liver stages known as 
hypnozoites extend the duration of P. vivax carriage in 
human hosts to weeks or months. While infected with 
hypnozoites, the host may become superinfected with a 
new strain. Thus, when the hypnozoites awaken, two ge-
netically distinct strains may be present and detectable 
in the bloodstream. 
Competition between co-infecting parasite clones for 
limited resources within a host is a major factor in the 
evolution of phenotypes such as virulence, transmissi-
bility and drug resistance (Mackinnon & Read 2004). 
A series of elegant experiments with mice co-infected 
with different strains of Plasmodium chabaudi revealed 
that competition favours strains with higher virulence 
(de Roode et al. 2005, Bell et al. 2006), greater gameto-
cyte production and increased transmissibility to mos-
quitoes (Taylor et al. 1997, de Roode et al. 2005). Early 
gametogenesis allows P. vivax transmission to occur 
before symptoms appear and, thus, before drug treat-
ment is started. This can lead to increased gametocyte 
production in multiple-clone infections, which may have 
a major public health impact even in those areas where 
early diagnosis and treatment of malaria can be achieved 
(Sattabongkot et al. 2004). In addition, when clone mix-
tures are comprised of drug-resistant and drug-sensitive 
P. chabaudi strains, the removal of susceptible clones by 
drug therapy promoted the expansion of resistant para-
sites to a level far beyond that achieved when a competi-
tor had never been present (Wargo et al. 2007). There-
fore, these experimental results imply that within-host 
competition may accelerate the spread of drug resistance 
in malaria parasites. 
Whether or not similar effects occur in human co-in-
fections with genetically diverse P. vivax strains remains 
unknown (Mackinnon & Read 2004). The increasing 
virulence of P. vivax strains, as demonstrated by numer-
TABLE 
Proportions of isolates with multiple clones detected with different molecular markers in Plasmodium vivax populations 
 Papua New Guinea Asia Americas
Markers % (n) % (n) % (n)
Microsatellites  Thailand: 63.6 (88)i, 52.8 (36)j Brazil: 48.0(25)k, 49.0 (49)k
  India: 47.8 (67)i, 10.5 (38)j Colombia: 38.6 (43)i
  Sri Lanka: 9.1(22)m, 60.0 (20)m Mexico: 15.8 (234)n
  Laos: 58.6 (71)i
  Myanmar: 65.3 (75)i 
CSP 32.5 (40)b Thailand: 25.6 (90)e Guyana: 39.3 (61)f
  India: 1.3 (151)g 
MSP-1 37.5 (40)b Thailand: 7.1 (14)d Brazil: 47.8 (23)a
  India: 0.7 (151)g 
GAM-1  India: 13.1 (252)h 
MSP3α 22.7 (22)c Thailand: 19.3 (90)e
  India: 8.6 (151)g
  Sri Lanka: 12.8 (39)l 
a: Porto et al. 1992 ; b: Kolakovich et al. 1996; c: Bruce et al. 1999; d: Putaporntip et al. 2000; e: Cui et al. 2003; f: Bonilla et al. 
2006; g: Kim et al. 2006; h: Prajapati et al. 2006; i: Inwong et al. 2007a; j: Inwong et al. 2007b; k: Ferreira et al. 2007; l: Guna-
sekera et al. 2007; m: Karunaweera et al. 2007; n: Joy et al. 2008; CSP: circumsporozoite protein; GAM1: gametocyte antigen 1; 
MSP1: merozoite surface protein 1; MSP3α: merozoite surface protein 3α.
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ous reports of severe vivax malaria worldwide (Roger-
son & Carter 2008), and the emergence of chloroquine 
resistance in this species (Baird 2004) are a possible 
consequences of intra-host competition. The recently in-
creasing tolerance of P. vivax hypnozoites to primaquine 
(Baird & Rickmann 2003), the only anti-relapse drug cur-
rently in clinical use, may have favoured multiple-clone 
infections in several endemic settings due to superinfec-
tion with new strains in patients already carrying relaps-
ing parasites. The available data led Galvani (2003) to 
suggest that reducing the proportion of multiple-clone 
infections at the population level could have a major pub-
lic health impact by decreasing within-host competition 
and the corresponding selection for increased virulence, 
transmissibility and/or drug resistance.   
Finally, multiple-clone infections may hamper the 
molecular detection of P. vivax relapses in patients con-
tinuously exposed to malaria transmission. The distinct 
ability of P. vivax to stay dormant in host liver cells 
and cause relapses weeks or months after the primary 
infection complicates the assessment of sequential ma-
laria episodes in observational studies and clinical tri-
als (Baird & Rieckmann 2003). Until recently, relapses 
were thought to be caused by hypnozoites that are ge-
netically identical to the blood-stage parasites found in 
primary infections (Craig & Kain 1996, Kirchgatter & 
del Portillo 1998). This suggested that molecular meth-
ods could easily discriminate relapses, which would 
have the same genotype as the primary infection, from 
new infections, which would have a different genotype. 
This view has been challenged by the recent discovery 
of different parasite genotypes in primary infections 
and relapses in 72% of P. vivax-infected patients from 
Thailand, India and Myanmar (Imwong et al. 2007b). 
Accurate detection of multiple-clone P. vivax infections 
becomes even more important in light of this report. If 
the primary infection comprises multiple clones, some of 
them may have been missed, partially characterized or, 
even worse, had their alleles combined to create artificial 
haplotypes during genotyping. Likewise, the relapsing 
clone could have been missed or incorrectly typed dur-
ing the primary infection, leading to a false conclusion 
that different genotypes were present during the primary 
and relapse infections.
Concluding remarks
Multiple-clone infections with P. vivax have been 
shown to be highly prevalent worldwide, even in areas 
with relatively low levels of malaria transmission. Lim-
ited available data suggests that clonal diversity may be 
even higher in P. vivax than in P. falciparum populations 
co-circulating in the same area. One possible explana-
tion for this is that parasite relapses extend the duration 
of P. vivax carriage and increase the probability that se-
quential infection with different strains occurs while the 
relapsing clone is still present. 
Experimental rodent malaria models clearly show 
that the co-existence of two or more genetically distinct 
clones in the same host increases the rate of evolution 
of important phenotypes, such as increased virulence, 
transmissibility and drug resistance, through intra-host 
competition. Although the evolutionary consequences 
of multiple-clone P. vivax infections remain largely un-
known, the recent emergence of more virulent strains 
and widespread drug resistance suggests that competi-
tive interactions between co-infecting clones may have 
shaped the recent evolution of this major human malar-
ia parasite. Public health interventions to decrease the 
prevalence of multiple-clone infections might, therefore, 
have enormously beneficial consequences. 
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